NCT06812390

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Albumin Assisted Diuresis in Patients with Cirrhosis Decompensated by Ascites and Peripheral Edema, a Proof-of-concept Double Blind Randomized Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Anahita Rabiee MD MHS · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.

Conditions

• Cirrhosis
• Ascites Hepatic

Interventions

Type	Name	Description
DRUG	Albumin infusion (25% albumin)	Albumin 25 gram infusion
DRUG	Normal Saline (0.9% NaCl)	100 cc of normal saline

Timeline

• Start date: 2025-02-28
• Primary completion: 2026-12-01
• Completion: 2027-03-01
• First posted: 2025-02-06
• Last updated: 2025-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study